Replies to post #180669 on Biotech Values

[justrpaul]

Sorry, I didn't get to stick with the whole call. "Seeking ALpha" usually has transcripts.

[DewDiligence]

GBIM -60% PM on failure of phase-2 HBV trial of GS-4774, which is partnered with GILD:

http://finance.yahoo.com/news/globeimmune-announces-top-line-results-103000148.html

…patients treated with the highest dose of GS-4774 plus ongoing oral antiviral therapy (OAV) did not show a reduction in hepatitis B surface antigen (HBsAg) at week 24, the primary endpoint of the study, but at 48 weeks had a mean -0.17 log10 reduction of HBsAg compared with a -0.04 log10 reduction in the OAV alone group (p=not significant).